123 related articles for article (PubMed ID: 20646614)
1. [Drug resistance mechanism of non small cell lung cancer PC9/AB2 cell line with acquired drug resistance to gefitinib].
Ju LX; Zhou CC; Tang L; Zhao YM; Yang XJ; Su B; Meng SY; Li W; Yan LH; Ding YM
Zhonghua Jie He He Hu Xi Za Zhi; 2010 May; 33(5):354-8. PubMed ID: 20646614
[TBL] [Abstract][Full Text] [Related]
2. [Sensitivity of two cell lines with acquired resistance to gefitinib to several chemotherapeutic drugs].
Deng QF; Su B; Zhao YM; Zhou CC
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):813-6. PubMed ID: 19173824
[TBL] [Abstract][Full Text] [Related]
3. Integrin beta1 over-expression associates with resistance to tyrosine kinase inhibitor gefitinib in non-small cell lung cancer.
Ju L; Zhou C; Li W; Yan L
J Cell Biochem; 2010 Dec; 111(6):1565-74. PubMed ID: 21053345
[TBL] [Abstract][Full Text] [Related]
4. 5-Aza-CdR can reverse gefitinib resistance caused by DAPK gene promoter methylation in lung adenocarcinoma cells.
Yang B; Yang ZG; Gao B; Shao GG; Li GH
Int J Clin Exp Pathol; 2015; 8(10):12961-6. PubMed ID: 26722491
[TBL] [Abstract][Full Text] [Related]
5. [Effect of Wnt signaling suppression on gefitinib in non small cell lung cancer cell lines].
Fang X; Gu P; Zhou CC; Ren SX; Luo BF; Zeng Y; Wu YJ; Zhao YM; Zhu XY; Yi XH
Zhonghua Bing Li Xue Za Zhi; 2013 Jul; 42(7):455-9. PubMed ID: 24246864
[TBL] [Abstract][Full Text] [Related]
6. [Relationship between EGFR Promoter Region Methylation and Secondary Resistance Which may be Induced by Gefitinib].
Wang Q; Li M; Hu C
Zhongguo Fei Ai Za Zhi; 2015 Apr; 18(4):193-8. PubMed ID: 25936882
[TBL] [Abstract][Full Text] [Related]
7. Blocking the PI3K/AKT and MEK/ERK signaling pathways can overcome gefitinib-resistance in non-small cell lung cancer cell lines.
Li H; Schmid-Bindert G; Wang D; Zhao Y; Yang X; Su B; Zhou C
Adv Med Sci; 2011; 56(2):275-84. PubMed ID: 22037177
[TBL] [Abstract][Full Text] [Related]
8. FGL1 regulates acquired resistance to Gefitinib by inhibiting apoptosis in non-small cell lung cancer.
Sun C; Gao W; Liu J; Cheng H; Hao J
Respir Res; 2020 Aug; 21(1):210. PubMed ID: 32778129
[TBL] [Abstract][Full Text] [Related]
9. Oct4 plays a crucial role in the maintenance of gefitinib-resistant lung cancer stem cells.
Kobayashi I; Takahashi F; Nurwidya F; Nara T; Hashimoto M; Murakami A; Yagishita S; Tajima K; Hidayat M; Shimada N; Suina K; Yoshioka Y; Sasaki S; Moriyama M; Moriyama H; Takahashi K
Biochem Biophys Res Commun; 2016 Apr; 473(1):125-132. PubMed ID: 26996130
[TBL] [Abstract][Full Text] [Related]
10. The impact of intermittent versus continuous exposure to EGFR tyrosine kinase inhibitor on selection of EGFR T790M-mutant drug-resistant clones in a lung cancer cell line carrying activating EGFR mutation.
Lee Y; Choi YR; Kim KY; Shin DH
Oncotarget; 2016 Jul; 7(28):43315-43323. PubMed ID: 27270313
[TBL] [Abstract][Full Text] [Related]
11. Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer.
Wu M; Yuan Y; Pan YY; Zhang Y
Mol Med Rep; 2014 Aug; 10(2):931-8. PubMed ID: 24840891
[TBL] [Abstract][Full Text] [Related]
12. [c-Met signaling pathway participating in the gefitinib resistance of different gene types of non-small cell lung cancer cells induced by HGF in vitro].
Xuan X; An C; Zhou C
Zhongguo Fei Ai Za Zhi; 2013 Sep; 16(9):464-9. PubMed ID: 24034993
[TBL] [Abstract][Full Text] [Related]
13. [Relationship between Mutations of the Epidermal Growth Factor Receptor Gene and Drug-Resistance to Gefitinib in Human Lung Cancer in vitro.].
Wei W; Fan Y; Liu H; Wu Z; Wan H; Yan Z; Xu K; Zhou Q
Zhongguo Fei Ai Za Zhi; 2009 Jan; 12(1):28-32. PubMed ID: 20712953
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
[TBL] [Abstract][Full Text] [Related]
15. Identification of protein expression alterations in gefitinib-resistant human lung adenocarcinoma: PCNT and mPR play key roles in the development of gefitinib-associated resistance.
Lin CC; Chen JT; Lin MW; Chan CH; Wen YF; Wu SB; Chung TW; Lyu KW; Chou HC; Chan HL
Toxicol Appl Pharmacol; 2015 Nov; 288(3):359-73. PubMed ID: 26298006
[TBL] [Abstract][Full Text] [Related]
16. Activation of the FGF2-FGFR1 autocrine pathway: a novel mechanism of acquired resistance to gefitinib in NSCLC.
Terai H; Soejima K; Yasuda H; Nakayama S; Hamamoto J; Arai D; Ishioka K; Ohgino K; Ikemura S; Sato T; Yoda S; Satomi R; Naoki K; Betsuyaku T
Mol Cancer Res; 2013 Jul; 11(7):759-67. PubMed ID: 23536707
[TBL] [Abstract][Full Text] [Related]
17. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
[TBL] [Abstract][Full Text] [Related]
18. [Screening and identification of microRNAs related to acquired gefitinib-resistance in lung adenocarcinoma cell lines].
Qin X; Liu B; Li Y; You J; Zhou Q
Zhongguo Fei Ai Za Zhi; 2011 Jun; 14(6):478-83. PubMed ID: 21645449
[TBL] [Abstract][Full Text] [Related]
19. CpG hypermethylation contributes to decreased expression of PTEN during acquired resistance to gefitinib in human lung cancer cell lines.
Maeda M; Murakami Y; Watari K; Kuwano M; Izumi H; Ono M
Lung Cancer; 2015 Mar; 87(3):265-71. PubMed ID: 25638724
[TBL] [Abstract][Full Text] [Related]
20. γ Secretase inhibitor BMS-708163 reverses resistance to EGFR inhibitor via the PI3K/Akt pathway in lung cancer.
Xie M; He J; He C; Wei S
J Cell Biochem; 2015 Jun; 116(6):1019-27. PubMed ID: 25561332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
